Skip to Main Content

Paper Details

Intratumoral CD16+ Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy.
Clin Cancer Res
7
2023
+ macrophages, Anti-PD-1, CD16, CD16+, CD16+ macrophage, CD16+ macrophages, CTLA-4, CXCL10, CXCL11, CXCL9, FcRIIIa, FcRIIIa (, Intratumoral CD16+ Macrophages, Macrophage populations, Melanoma, Metastatic Melanoma, PD-1, Patients, advanced melanoma, anti-CTLA-4, anti-PD-1, intratumoral macrophage populations, melanoma, metastatic melanoma, patients, tumor
Author NameAffiliation
Nicholas K HaywardQIMR Berghofer Medical Research Institute
Nicholas K HaywardQIMR Berghofer Medical Research Institute
Nicola WaddellQIMR Berghofer Medical Research Institute
Nicola WaddellQIMR Berghofer Medical Research Institute
Richard A ScolyerMelanoma Institute Australia, The University of Sydney
Richard A ScolyerThe University of Sydney
Richard A ScolyerThe University of Sydney
Richard A ScolyerRoyal Prince Alfred Hospital
Richard A Scolyer
Georgina V LongMelanoma Institute Australia, The University of Sydney
Georgina V LongThe University of Sydney
Georgina V LongThe University of Sydney
Georgina V LongRoyal North Shore Hospital
Georgina V LongMater Hospital
  • 1 - 14

Datasets

Release 1.2